JP2014513953A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014513953A5 JP2014513953A5 JP2014506589A JP2014506589A JP2014513953A5 JP 2014513953 A5 JP2014513953 A5 JP 2014513953A5 JP 2014506589 A JP2014506589 A JP 2014506589A JP 2014506589 A JP2014506589 A JP 2014506589A JP 2014513953 A5 JP2014513953 A5 JP 2014513953A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- region
- bms3h
- antibody polypeptide
- gly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 28
- 229920001184 polypeptide Polymers 0.000 claims 27
- 102000004196 processed proteins & peptides Human genes 0.000 claims 27
- 150000001413 amino acids Chemical class 0.000 claims 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 230000004927 fusion Effects 0.000 claims 3
- 208000026278 immune system disease Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 101150013553 CD40 gene Proteins 0.000 claims 2
- 101100099884 Homo sapiens CD40 gene Proteins 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000000104 Arthus reaction Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010003645 Atopy Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000020446 Cardiac disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 208000022555 Genital disease Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000001204 Hashimoto Disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000012659 Joint disease Diseases 0.000 claims 1
- 206010024229 Leprosy Diseases 0.000 claims 1
- 208000007466 Male Infertility Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010034038 Parotitis Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 230000036783 anaphylactic response Effects 0.000 claims 1
- 208000003455 anaphylaxis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 210000004351 coronary vessel Anatomy 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 208000007475 hemolytic anemia Diseases 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161477904P | 2011-04-21 | 2011-04-21 | |
| US61/477,904 | 2011-04-21 | ||
| PCT/US2012/034519 WO2012145673A1 (en) | 2011-04-21 | 2012-04-20 | Antibody polypeptides that antagonize cd40 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017000493A Division JP2017099391A (ja) | 2011-04-21 | 2017-01-05 | Ｃｄ４０を拮抗する抗体ポリペプチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014513953A JP2014513953A (ja) | 2014-06-19 |
| JP2014513953A5 true JP2014513953A5 (enExample) | 2015-04-23 |
| JP6114256B2 JP6114256B2 (ja) | 2017-04-12 |
Family
ID=46000407
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014506589A Expired - Fee Related JP6114256B2 (ja) | 2011-04-21 | 2012-04-20 | Ｃｄ４０を拮抗する抗体ポリペプチド |
| JP2017000493A Pending JP2017099391A (ja) | 2011-04-21 | 2017-01-05 | Ｃｄ４０を拮抗する抗体ポリペプチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017000493A Pending JP2017099391A (ja) | 2011-04-21 | 2017-01-05 | Ｃｄ４０を拮抗する抗体ポリペプチド |
Country Status (35)
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3556774B1 (en) | 2011-03-11 | 2024-01-03 | Beth Israel Deaconess Medical Center Inc. | Anti-cd40 antibodies and uses thereof |
| AR086360A1 (es) | 2011-04-21 | 2013-12-11 | Bristol Myers Squibb Co | Polipeptidos anticuerpos que antagonizan cd40 |
| WO2012149356A2 (en) | 2011-04-29 | 2012-11-01 | Apexigen, Inc. | Anti-cd40 antibodies and methods of use |
| SMT202000091T1 (it) | 2011-10-13 | 2020-05-08 | Bristol Myers Squibb Co | Polipeptidi anticorpali che antagonizzano cd40l |
| CN104918957B (zh) | 2012-10-30 | 2018-11-16 | 埃派斯进有限公司 | 抗-cd40抗体及其使用方法 |
| EP3113796A1 (en) | 2014-03-07 | 2017-01-11 | Bristol-Myers Squibb Company | Method of using antibody polypeptides that antagonize cd40 to treat ibd |
| CN113699116A (zh) | 2014-12-10 | 2021-11-26 | 明尼苏达大学董事会 | 用于治疗疾病的遗传修饰的细胞、组织和器官 |
| EP3750918A1 (en) | 2015-01-20 | 2020-12-16 | IGM Biosciences, Inc. | Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof |
| MA41459A (fr) * | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l |
| EP3303402A4 (en) * | 2015-05-27 | 2019-05-01 | La Jolla Biologics, Inc. | ANTIBODIES TO GLYPICAN-3 AND ITS USE TO CANCER DIAGNOSIS AND TREATMENT |
| RU2715597C2 (ru) | 2015-05-29 | 2020-03-02 | Эббви Инк. | Антитела к cd40 и способы их применения |
| KR20250007054A (ko) | 2015-09-04 | 2025-01-13 | 프리마토프 테라퓨틱스 인크. | 인간화 항-cd40 항체 및 그의 용도 |
| US20190086405A1 (en) | 2016-03-16 | 2019-03-21 | Bristol-Myers Squibb Company | Methods of diagnosing and treating lupus |
| TWI640536B (zh) | 2016-06-20 | 2018-11-11 | 克馬伯有限公司 | 抗體 |
| WO2018088850A2 (ko) | 2016-11-11 | 2018-05-17 | 다이노나(주) | Cd40에 특이적으로 결합하는 항체 및 그의 용도 |
| WO2018115003A2 (en) | 2016-12-19 | 2018-06-28 | Glenmark Pharmaceuticals S.A. | Novel tnfr agonists and uses thereof |
| EP3600421A4 (en) * | 2017-03-23 | 2021-01-06 | The Trustees of The University of Pennsylvania | ANTI-C5A ANTIBODIES AND USES OF THEM |
| MA50435A (fr) | 2017-05-24 | 2020-09-02 | Als Therapy Development Inst | Anticorps anti-ligand anti-cd40 thérapeutiques |
| EP3630832A1 (en) * | 2017-05-25 | 2020-04-08 | Bristol-Myers Squibb Company | MODIFIED IgG1 Fc DOMAINS AND ANTI-CD40 DOMAIN ANTIBODY FUSIONS THEREWITH |
| JP7257335B2 (ja) | 2017-05-25 | 2023-04-13 | ブリストル－マイヤーズ スクイブ カンパニー | アンタゴニスト性ｃｄ４０モノクローナル抗体およびその使用 |
| US20210340250A1 (en) | 2017-05-30 | 2021-11-04 | Bristol-Myers Squibb Company | Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent |
| AU2018278051A1 (en) * | 2017-06-01 | 2020-01-30 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof |
| KR20210035805A (ko) | 2018-06-15 | 2021-04-01 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가 |
| AR117091A1 (es) | 2018-11-19 | 2021-07-07 | Bristol Myers Squibb Co | Anticuerpos monoclonales antagonistas contra cd40 y sus usos |
| WO2020108621A1 (zh) | 2018-11-30 | 2020-06-04 | 江苏恒瑞医药股份有限公司 | 一种cd40抗体药物组合物及其用途 |
| BR112021009835A2 (pt) * | 2018-11-30 | 2021-08-17 | Jiangsu Hengrui Medicine Co., Ltd. | anticorpo anti-cd40, fragmento de ligação ao antígeno e uso farmacêutico dos mesmos |
| CA3128148A1 (en) * | 2019-02-01 | 2020-08-06 | Lava Therapeutics B.V. | Novel cd40-binding antibodies |
| EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
| US20210032356A1 (en) * | 2019-08-02 | 2021-02-04 | Eastern Virginia Medical School | Method for treating seizures |
| EP4076434A1 (en) | 2019-12-17 | 2022-10-26 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| AU2020405230A1 (en) | 2019-12-20 | 2022-06-23 | Amgen Inc. | Mesothelin-targeted CD40 agonistic multispecific antibody constructs for the treatment of solid tumors |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| US11862306B1 (en) | 2020-02-07 | 2024-01-02 | Cvs Pharmacy, Inc. | Customer health activity based system for secure communication and presentation of health information |
| US20230140868A1 (en) * | 2020-04-23 | 2023-05-11 | Alpha Beta Holdings, Llc | Compositions and methods for treating cancer |
| KR20230010725A (ko) | 2020-05-18 | 2023-01-19 | 브리스톨-마이어스 스큅 컴퍼니 | 개선된 약동학적 특성을 갖는 항체 변이체 |
| US20230355804A1 (en) | 2020-06-29 | 2023-11-09 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| CA3214085A1 (en) | 2021-03-31 | 2022-10-06 | Darby Rye Schmidt | Thanotransmission polypeptides and their use in treating cancer |
| EP4363059A1 (en) | 2021-06-29 | 2024-05-08 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| US12234294B2 (en) | 2021-11-05 | 2025-02-25 | Kiniksa Pharmaceuticals, Gmbh | Pharmaceutical composition of a humanized anti-CD40 antibody |
| CN114149508B (zh) * | 2021-11-25 | 2023-04-28 | 苏州普乐康医药科技有限公司 | 一种结合cd40l的融合蛋白及其应用 |
| CA3254481A1 (en) | 2022-03-08 | 2023-09-14 | Alentis Therapeutics Ag | USE OF ANTI-CLAUDIN-1 ANTIBODIES TO INCREASE T LYMPHOCYTE AVAILABILITY |
| CN116023495B (zh) * | 2022-09-05 | 2023-10-03 | 上海百英生物科技股份有限公司 | 一种抗cd40纳米抗体及其制备方法与应用 |
| EP4598946A1 (en) | 2022-10-05 | 2025-08-13 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| KR20250057233A (ko) | 2023-10-20 | 2025-04-29 | 한상진 | 이동식 무선 자동 제습기 |
| WO2025129007A1 (en) * | 2023-12-15 | 2025-06-19 | Werewool Inc. | Soy alginate fibers |
| WO2025184603A2 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration |
| US20250276092A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5247069A (en) | 1986-06-13 | 1993-09-21 | Oncogen | Ligands and methods for augmenting B-cell proliferation |
| US5182368A (en) | 1986-06-13 | 1993-01-26 | Ledbetter Jeffrey A | Ligands and methods for augmenting B-cell proliferation |
| US5506126A (en) | 1988-02-25 | 1996-04-09 | The General Hospital Corporation | Rapid immunoselection cloning method |
| CA2089229C (en) | 1992-02-14 | 2010-04-13 | Alejandro A. Aruffo | Cd40cr receptor and ligands therefor |
| US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
| NZ278740A (en) | 1993-12-23 | 1998-05-27 | Immunex Corp | Treating disease characterised by neoplastic cells expressing cd40 using a cd40 binding protein |
| PT892643E (pt) | 1996-03-20 | 2002-09-30 | Univ Emory | Metodos para inibir uma resposta imunitaria bloqueando os circuitos de gp39/cd40 e ctla4/cd28/b7 e composicoes utilizaveis para o efeito |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| US6051228A (en) | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
| JP4202127B2 (ja) * | 2000-10-02 | 2008-12-24 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | アンタゴニスト抗ｃｄ４０抗体を用いるｂ細胞悪性腫瘍の治療方法 |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| US8277810B2 (en) | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
| SG148143A1 (en) * | 2003-11-04 | 2008-12-31 | Novartis Vaccines & Diagnostic | Antagonist anti-cd40 monoclonal antibodies and methods for their use |
| ES2397631T3 (es) * | 2003-12-25 | 2013-03-08 | Kyowa Hakko Kirin Co., Ltd. | Mutante antagonista de anticuerpos ANTI-CD40 |
| ES2351509T3 (es) | 2004-03-24 | 2011-02-07 | Domantis Limited | Secuencia lider universal de gas1. |
| KR20070026522A (ko) | 2004-04-27 | 2007-03-08 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 길항제 항-ｃｄ40 모노클론 항체 및 이들의 사용 방법 |
| US7563443B2 (en) * | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| UA94213C2 (ru) | 2004-09-17 | 2011-04-26 | Домантис Лимитед | Применение полипептида одноцепочечного антитела, который подавляет активность cd40 или cd40l в приготовлении медикамента для лечения аутоиммунного заболевания |
| AR053579A1 (es) | 2005-04-15 | 2007-05-09 | Genentech Inc | Tratamiento de la enfermedad inflamatoria intestinal (eii) |
| US20070014720A1 (en) * | 2005-06-02 | 2007-01-18 | Gadi Gazit-Bornstein | Antibodies directed to CD20 and uses thereof |
| AR057253A1 (es) * | 2005-12-16 | 2007-11-21 | Genentech Inc | Anticuerpos anti-ox40l y metodos que los utilizan |
| JP2009523460A (ja) | 2006-01-24 | 2009-06-25 | ドマンティス リミテッド | Ｉｌ−４および／またはｉｌ−１３に結合するリガンド |
| US8945564B2 (en) | 2006-04-21 | 2015-02-03 | Novartis Ag | Antagonist anti-CD40 antibody pharmaceutical compositions |
| EP1854810A1 (en) | 2006-05-09 | 2007-11-14 | PanGenetics B.V. | Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody |
| GB0724331D0 (en) | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
| CN102083461B (zh) * | 2008-04-30 | 2014-09-17 | 伊缪诺金公司 | 有效的偶联物和亲水性连接体 |
| AU2009319856A1 (en) * | 2008-11-28 | 2010-06-03 | Abbvie Inc. | Stable antibody compositions and methods for stabilizing same |
| PT3178851T (pt) | 2010-03-31 | 2020-07-17 | Boehringer Ingelheim Int | Anticorpos anti-cd40 |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| AR086360A1 (es) | 2011-04-21 | 2013-12-11 | Bristol Myers Squibb Co | Polipeptidos anticuerpos que antagonizan cd40 |
-
2012
- 2012-04-20 AR ARP120101368A patent/AR086360A1/es unknown
- 2012-04-20 US US14/112,049 patent/US9475879B2/en active Active
- 2012-04-20 KR KR1020177011260A patent/KR101905346B1/ko not_active Expired - Fee Related
- 2012-04-20 TW TW101114258A patent/TW201245225A/zh unknown
- 2012-04-20 BR BR112013026828A patent/BR112013026828A2/pt not_active Application Discontinuation
- 2012-04-20 MX MX2013011966A patent/MX354243B/es active IP Right Grant
- 2012-04-20 DK DK12717027.2T patent/DK2699601T3/en active
- 2012-04-20 CN CN201710070840.9A patent/CN106977604A/zh active Pending
- 2012-04-20 EP EP12717027.2A patent/EP2699601B1/en active Active
- 2012-04-20 RS RS20180346A patent/RS57087B1/sr unknown
- 2012-04-20 TW TW105121984A patent/TWI598363B/zh not_active IP Right Cessation
- 2012-04-20 KR KR1020137030492A patent/KR101734614B1/ko not_active Expired - Fee Related
- 2012-04-20 SI SI201231203T patent/SI2699601T1/en unknown
- 2012-04-20 WO PCT/US2012/034519 patent/WO2012145673A1/en not_active Ceased
- 2012-04-20 ES ES12717027.2T patent/ES2664619T3/es active Active
- 2012-04-20 PT PT127170272T patent/PT2699601T/pt unknown
- 2012-04-20 PE PE2013002381A patent/PE20141188A1/es active IP Right Grant
- 2012-04-20 LT LTEP12717027.2T patent/LT2699601T/lt unknown
- 2012-04-20 SM SM20180228T patent/SMT201800228T1/it unknown
- 2012-04-20 CN CN201280030683.4A patent/CN103842382B/zh not_active Expired - Fee Related
- 2012-04-20 CA CA2833743A patent/CA2833743A1/en not_active Abandoned
- 2012-04-20 SG SG2013078183A patent/SG194561A1/en unknown
- 2012-04-20 NO NO12717027A patent/NO2699601T3/no unknown
- 2012-04-20 MY MYPI2013003839A patent/MY165090A/en unknown
- 2012-04-20 ME MEP-2018-94A patent/ME03071B/me unknown
- 2012-04-20 EP EP18151812.7A patent/EP3372616A1/en not_active Withdrawn
- 2012-04-20 HU HUE12717027A patent/HUE038848T2/hu unknown
- 2012-04-20 MA MA36322A patent/MA35035B1/fr unknown
- 2012-04-20 JP JP2014506589A patent/JP6114256B2/ja not_active Expired - Fee Related
- 2012-04-20 PL PL12717027T patent/PL2699601T3/pl unknown
- 2012-04-20 EA EA201391564A patent/EA030851B1/ru not_active IP Right Cessation
- 2012-04-20 HR HRP20180571TT patent/HRP20180571T1/hr unknown
- 2012-04-20 AU AU2012245309A patent/AU2012245309C1/en not_active Ceased
-
2013
- 2013-09-27 PH PH12013502013A patent/PH12013502013B1/en unknown
- 2013-10-03 IL IL228720A patent/IL228720B/en active IP Right Grant
- 2013-10-11 TN TNP2013000417A patent/TN2013000417A1/fr unknown
- 2013-10-21 CL CL2013003043A patent/CL2013003043A1/es unknown
- 2013-11-05 CO CO13261140A patent/CO6801649A2/es active IP Right Grant
-
2016
- 2016-04-27 AU AU2016202672A patent/AU2016202672B2/en not_active Ceased
- 2016-09-08 US US15/259,828 patent/US10544228B2/en active Active
-
2017
- 2017-01-05 JP JP2017000493A patent/JP2017099391A/ja active Pending
-
2018
- 2018-04-16 CY CY181100398T patent/CY1120637T1/el unknown
-
2019
- 2019-12-20 US US16/723,047 patent/US11136406B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014513953A5 (enExample) | ||
| JP2014530611A5 (enExample) | ||
| JP2017099391A5 (enExample) | ||
| AU2022279374B2 (en) | Improved immunoglobulin variable domains | |
| AU2016351710B2 (en) | Improved serum albumin-binding immunoglobulin variable domains | |
| JP2020521458A5 (enExample) | ||
| AU2016357460B2 (en) | Improved serum albumin binders | |
| CN108473563B (zh) | 改进的tnf结合剂 | |
| HRP20200230T1 (hr) | Polipeptidi antitijela koji antagoniziraju cd40l | |
| CN102905727B (zh) | Il-17a拮抗剂 | |
| TW200831533A (en) | Interleukin-13 binding proteins | |
| JP2017501711A5 (enExample) | ||
| CN106573053B (zh) | 干扰素α和ω抗体拮抗剂 | |
| RU2017134274A (ru) | Связывающие tslp белки | |
| JP2019503990A5 (enExample) | ||
| JP2014503209A5 (enExample) | ||
| TW201031421A (en) | IL-1 binding proteins | |
| JP2018537421A5 (enExample) | ||
| TW200911831A (en) | Polypeptides, antibody variable domains & antagonists | |
| JP2012500020A5 (enExample) | ||
| WO2015137843A1 (ru) | Анти-il-17-антитела, способ их получения и способ применения | |
| CN104105704A (zh) | Il4/il13结合重复蛋白及用途 | |
| JP2019504822A5 (enExample) | ||
| AU2016369307A1 (en) | Multi-specific antibody molecules having specificity for TNF-alpha, IL-17A and IL-17F | |
| JP2020171311A (ja) | 抗Ｐｒｅ−Ｓ１ ＨＢＶ抗体 |